RxDoctor Payments Data

Gordon Kritzer, MD

Interventional Cardiology · Seattle, WANPI 1518939420

Payments from drug & device makers

$351in general payments, 2019–2025

Across 7 payments — averaging $50.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$206
  • Boston Scientific$37
  • Novartis$33
  • Irhythm Technologies, Inc.$26
  • Abbott$25
  • Shockwave Medical, Inc$23

What the payments were for

  • Food & beverage$351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$351 in reported general payments places this provider in the 10th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$199,006
Medicare patients
1,151
Services billed
2,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban301$370,508
VyndamaxTafamidis11$235,320
XareltoRivaroxaban92$129,592
Repatha SyringeEvolocumab63$61,478
Repatha SureclickEvolocumab33$53,207
JardianceEmpagliflozin29$35,383
EntrestoSacubitril/Valsartan27$19,363
Metoprolol Succinate506$8,019
Atorvastatin Calcium450$5,219
Ranolazine ErRanolazine40$4,317
Rosuvastatin Calcium203$2,760
Prasugrel Hcl32$2,690
ClopidogrelClopidogrel Bisulfate150$2,301
Isosorbide Mononitrate ErIsosorbide Mononitrate98$1,760
Losartan Potassium157$1,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$206$129,59292 claims
NovartisEntresto$33$19,36327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →